Clinical Trial Goal
To find out:
- The highest dose of mezigdomide and revumenib that's safe to give
- If the combination of mezigdomide and revumenib is safe and works well to treat acute leukemia that is mutated and has relapsed or is refractory in children and adults
You may be able to join this trial if you:
- Are 12 years old or older
- Have acute leukemia that has relapsed or is refractory. Some examples include:
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Mixed phenotype acute leukemia (MPAL)
- Have cancer cells with one of the following mutations or rearrangements:
- KMT2A+
- NPMI+
- NUP98+
- Do not have acute promyelocytic leukemia (APL)
- Have not been treated with mezigdomide
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 2 months
- Do not have active graft-versus-host-disease (GVHD)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Mezigdomide is an immunomodulatory drug that doctors think will help fight cancer cells.
Revumenib is a menin inhibitor that blocks interaction between the menin protein and the KMT2A protein.
You’ll get:
Revumenib is a menin inhibitor that blocks interaction between the menin protein and the KMT2A protein.
You’ll get:
- Mezigdomide– The dose you'll get depends on when you start the trial and how safe it has been
- Revumenib – The dose you'll get depends on when you start the trial and how safe it has been
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for about 1 year.
The Food and Drug Administration (FDA) has not yet approved mezigdomide.
Contacts
Eytan Stein, MD, 646-608-3749, SteinE@mskcc.org
Neerav Shukla, MD, 212-639-5158, shuklan@MSKCC.ORG
Locations
Sponsors
lead: Memorial Sloan Kettering Cancer Center
